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ABSTRACT
Objectives Patients undergoing haemodialysis report 
elevated symptoms and reduced health- related quality 
of life, and often prioritise improvements in psychosocial 
well- being over long- term survival. Systematic collection 
and use of patient- reported outcomes (PROs) may help 
support tailored healthcare and improve outcomes. This 
study investigates the methodological basis for routine 
PRO assessment, particularly using electronic formats 
(ePROs), to maximise the potential of PRO use, through 
exploration of the experiences, views and perceptions 
of patients and healthcare professionals (HCPs) on 
implementation and use of PROs in haemodialysis settings.
Study design Qualitative study.
Setting and participants Semistructured interviews with 
22 patients undergoing haemodialysis, and 17 HCPs in the 
UK.
Analytical approach Transcripts were analysed 
deductively using the Consolidated Framework for 
Implementation Research (CFIR) and inductively using 
thematic analysis.
Results For effective implementation, the potential 
value of PROs needs to be demonstrated empirically to 
stakeholders. Any intervention must remain flexible enough 
for individual and aggregate use, measuring outcomes 
that matter to patients and clinicians, while maintaining 
operational simplicity. Any implementation must sit 
within a wider framework of education and support for 
both patients and clinicians who demonstrate varying 
previous experience of using PROs and often confuse 
related concepts. Implementation plans must recognise 
the multidimensionality of end- stage kidney disease 
and treatment by haemodialysis, while acknowledging 
the associated challenges of delivering care in a highly 
specialised environment. To support implementation, 
careful consideration needs to be given to barriers and 
facilitators including effective leadership, the role of 
champions, effective launch and ongoing evaluation.
Conclusions Using the CFIR to explore the experiences, 
views and perceptions of key stakeholders, this study 
identified key factors at organisational and individual levels 
which could assist effective implementation of ePROs in 
haemodialysis settings. Further research will be required 
to evaluate subsequent ePRO interventions to demonstrate 
the impact and benefit to the dialysis community.
INTRODUCTION
The prevalence of end- stage kidney disease 
(ESKD) requiring treatment with renal 
replacement therapies such as haemodial-
ysis (HD) continues to rise worldwide.1 Both 
underlying disease and treatment are associ-
ated with a high symptom burden and reduced 
health- related quality of life (HRQoL).2 3 
Historically, outcomes such as mortality and 
Strengths and limitations of this study
 ► Qualitative methods yield rich data with face- to- face 
semistructured interviews allowing the interviewer 
to monitor non- verbal communications and clarify 
ambiguous responses.
 ► This study involved explorations of a prospective 
intervention, meaning some participants were un-
familiar with key concepts. Preinterview materials 
were shared to support and inform discussion and 
participation.
 ► The role of the researchers was carefully considered 
to acknowledge and minimise bias associated with 
beliefs and values. Steps were taken to mitigate 
risks, including use of reflective diaries, participant 
checking and multiple researchers involved in the 
coding process.
 ► While purposive sampling methods led to a diverse 
sample of participants, it is acknowledged that the 
sample did not include non- English speakers or car-
ers. Further research is required.
 ► Data were collected before the coronavirus pan-
demic. The healthcare delivery landscape in the UK 
has changed, and it is possible that some attitudes 
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dialysis adequacy based on biomedical parameters have 
been used to inform the management of dialysis services 
and individual care.4 However, there is now a body of 
established research5–10 demonstrating the importance of 
also capturing patient- reported outcomes (PROs). PRO 
measures capture data directly from patients on how they 
feel or function, without requiring interpretation from 
others, using standardised symptom and/or QoL ques-
tionnaires,11 and are often in electronic format (ePROs).
However, while patient- reported experience measures 
(PREMs), which allow patients to self- report their expe-
rience of receiving healthcare, have been collected since 
2017,12 PROs are still not routinely and systematically 
collected to manage individual patient care in the UK: 
meaning that many patients and some members of the 
multidisciplinary team caring for them are inexperienced 
in PROs and related concepts.
Yet the international body of evidence exploring 
the use of PROs in nephrology settings is growing,13–22 
demonstrating acceptability and feasibility of ePRO 
capture23–25 and how ePROs can support the delivery 
of patient- centred care.26 27 However, the overall impact 
and benefit of PRO use in dialysis care is yet to be estab-
lished.28 In comparison, PRO research in oncology has 
shown defined benefits ranging from improved QoL and 
reduction in hospitalisations to overall survival29 and even 
cost- effectiveness.30
In November 2020, an online UK Summit led by the 
UK Renal Association, entitled ‘ePROs for the Kidney 
Patient Community’, was held to create a comprehensive, 
UK- wide roadmap to facilitate and optimise the collection 
and use of ePROs for the benefit of people with chronic 
kidney disease (CKD). This summit highlighted the 
importance of key stakeholder engagement, including 
patients and front- line clinicians, early and at all stages of 
design and implementation.31
To inform and direct future research plans, this study 
aimed to investigate the methodological basis for routine 
PRO assessment through exploration of the experiences, 
views and perceptions of patients and healthcare profes-
sionals (HCPs) on implementation and use of PROs, 
particularly ePROs, in HD settings.
METHODS
Design
The qualitative research question: ‘What are the experi-
ences, views and perceptions of patients undergoing HD 
on the implementation and use of ePROs in routine care 
and research settings?’
Epistemologically, pragmatism, which is set within a 
paradigm of enquiry processes and research practicality,32 
provides the philosophical framework to answer this ques-
tion. A core assumption of pragmatism is that research 
should proceed from a wish to produce actionable knowl-
edge33; allowing the researcher to select the research 
design and the methodology deemed most appro-
priate.34 These foundations led to the decision to use the 
Consolidated Framework for Implementation Research35 
to offer a theoretical perspective and a qualitative descrip-
tive (QD) methodology.36–38 This is particularly useful for 
healthcare studies focused on discovering the who, what 
and where of events or experiences and gaining under-
standing of inadequately understood phenomenon. Kim 
et al38 describe QD as the ‘label of choice’ when an unam-
biguous description of a phenomenon is desired or infor-
mation is sought to develop and refine questionnaires or 
interventions.39 This choice of methodology led to the 
utilisation of the following methods.
Participant selection
Participants included adults (≥18 years), receiving HD 
(in centre or at home), able to provide valid informed 
consent and converse in everyday English. Patients were 
excluded if they were not deemed established on HD or 
had been undergoing HD <3 months, or if they had an 
active intercurrent medical problem requiring enhanced 
routine clinical care.40 Participants were identified and 
recruited between July 2018 and November 2019 by the 
lead author. Eligible patients were primarily approached 
face to face in the dialysis unit; patients dialysing in centre 
were approached before dialysis session and patients who 
dialysed at home (home haemodialysis (HHD)) were 
approached when they attended for clinic. Purposive 
sampling was undertaken to achieve maximum variation 
across age, gender, ethnicity, time on dialysis and comor-
bidities.41 HCPs were recruited from the broader renal 
team, and initially contacted by email by the lead author; 
they included healthcare and administrative assistants.40
Setting
Data were collected from 22 patients undergoing HD and 
17 HCPs in the UK (see tables 1 and 2). All participants 
were being treated via, or working at, a large regional 
hospital. To accurately reflect the diversity within the 
dialysis population, patients being treated in centre 
(n=15) were recruited from two satellite units as well as 
seven patients choosing to dialyse at home. Non- medical 
members of the multidisciplinary team were targeted 
from these two units, one in a city and one serving mainly 
rural communities. All HCPs currently working in the 
home setting (n=5) had extensive previous experience of 
in- centre dialysis delivery.
Data collection
All consenting participants took part in an audio- recorded 
semistructured interview with the lead author, either face 
to face or by telephone. Ethical approval was gained for 
follow- up interviews, but none were required. Patient 
interviews were conducted at the dialysis unit for those 
dialysing in centre (n=15) and at home for the HHD 
group (n=7). Since these interviews were conducted in 
patient homes, family members were sometimes present 
at the request of the patient, but did not take an active 
role in the interview. HCPs were interviewed in a private 
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and support the interview process (see online supple-
mental files 1 and 2). These guides were piloted with one 
participant from each group and then refined iteratively 
during the collection phase in response to initial findings. 
Field notes and in- depth memos were created after each 
interaction. Since PROs are not routinely collected in the 
UK, including the hospital trust where this research was 
undertaken, it was recognised preinterview information 
was required to aid the quality of discussion around PROs 
and future implementation. Therefore, participants were 
provided with a diagram of a core outcome set selected 
specifically for use in HD trials, to illustrate the position 
of PROs in outcome measurement42 and example PROs 
from a recent systematic review and supported by our 
local renal public and patient involvement group: Kidney 
Disease Quality of Life Short Form,43 Kidney Disease 
Quality of Life 3644 and Integrated Patient Outcome 
Scale- Renal.45 Patients in all UK renal units are invited to 
complete the annual renal PREM to report their experi-
ence of kidney care. This report demonstrates variation 
in experience across centres and can be used to drive 
organisational change and improvement12; some patient 
Table 1 Patient participant characteristics
Variable Count (%)
Age
  <40 2/22 (9)
  40–49 3/22 (13)
  50–59 5/22 (23)
  60–69 3/22 (14)
  70–79 6/22 (27)
  >80 3/22 (13)
  Gender
  Male 12/22 (55)











  In- centre
  dialysis
15/22 (68)
  Morning sessions 12/15 (80)
  Home HD 7/22 (32)
Current vascular access
  Arteriovenous fistula 19/22 (86)
  Arteriovenous graft 0/22 (0)
  Central venous catheter 3/22 (14)
Charlson Comorbidity Score
  <2 1 (4)
  3–4 5 (23)
  5–6 4 (18)
  7–8 6 (27)
  9–10 5 (23)
  11–12 1 (4)
  13+ 0 (0)
Time since dialysis commencement (years)
  ≤5 11/22 (50)
  6–10 5/22 (23)
  11–15 3/22 (14)
  16–20 1/22 (4.5)
  >20 2/22 (9)
Charlson Comorbidity Index (CCI)65 quantifies an individual’s 
burden of disease and corresponding 1- year mortality risk. The 
index adjusts for 17 comorbidities, each one classified with a 
validated score of 1–6 points, based on the adjusted relative risk 
of 1‐year mortality. The final total score is used to calculate the 
probability of survival. The index is being used in this context to 




Table 2 Healthcare professional participant characteristics
Variable Count (%)
Gender
  Male 5/17 (29)
  Female 12/17 (71)
Ethnicity (Office of National Statistics categories)
  White British 9/17 (53)
  Other white background 2/17 (12)
  Black British 1/17 (6)
  Asian/Asian British 1/17 (6)
  Any other Asian background 2/17 (12)
  Black African 1/17 (6)
  White and Black Caribbean 1/17 (6)
Role
  Consultant nephrologist 5/17 (29)
  Consultant surgeon 1/17 (6)
  Registered nurse 9/17 (53)
  Non- registered healthcare assistant 1/17 (6)
  Administrative assistant 1/17 (6)
Time working across HD setting (years)
  ≤5 1/17 (6)
  6–10 4/17 (24)
  11–15 3/17 (18)
  16–20 2/17 (12)
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participants indicated they had completed the annual 
PREM.
Analysis
Using codebook thematic analysis,46 a coding framework, 
drawing on the Consolidated Framework for Implemen-
tation Research (CFIR),35 was used to deductively analyse 
transcripts, with further new subthemes developed 
inductively through data engagement and the analytical 
process.
The CFIR is a widely used conceptual framework devel-
oped to guide systematic assessment of factors that might 
influence implementation and effectiveness, including 
assessing potential barriers and facilitators in prepara-
tion for implementing an innovation (see figure 1).35 47 
Primary data analysis was conducted by the lead author, 
with two investigators (CMcM, DK) reviewing coding for 
consistency and appropriateness. As the lead author was 
a renal research nurse conducting this research as part of 
a Clinical Doctoral Research Fellowship, she was known 
to some HCP participants. This information was declared 
and discussed during the valid informed consent process. 
Additionally, a reflective research diary, memo writing and 
discussion with the study management team were used 
to try to minimise the influence of prior relationships on 
analysis. Data analysis was supported by qualitative data 
analysis software—QSR NVivo V.12. Participant verifica-
tion,48 to check that the transcript correctly documented 
the discussion, was undertaken on one transcript from 
each group—no discrepant comments were reported. 
Data collection and analysis continued until saturation 
was achieved, that is, no new information pertinent to the 
research question was being generated by further inter-
views (see online supplemental tables 1 and 2).49
Patient and public involvement
Research on the use and implementation of PROs in 
nephrology settings was prioritised by the local kidney 
patients charity. An existing patient and public involve-
ment (PPI) group was used and a study- specific PPI group 
was convened to help develop the research question, 
design this study and the associated fellowship applica-
tion. Patients were consulted on the study documenta-
tion, including topic guides and example materials (see 
online supplemental files 1 and 2). A summary of study 
findings will be made available for study participants.
RESULTS
Participant characteristics
Participant characteristics are summarised in tables 1 and 
2.
The patient sample was broadly representative of prev-
alent HD population in the UK.50
Data saturation was deemed achieved after interviewing 
16 HCPs and 15 patients (see online supplemental tables 
1 and 2 for further detail).
Figure 1 Conceptual framework and key findings (adapted from Damschroder et al35). HD, haemodialysis; PREM, patient- 
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Key findings
Analysis identified the following themes, which are 
presented in line with the CFIR key domains. Although 
presented in a linear fashion, the five domains and their 
respective constructs cannot be considered in isolation, 
all interact to effect implementation.
Figure 1 shows the conceptual framework and asso-
ciated findings. Illustrative quotations are provided in 
table 3.
Intervention characteristics: factors associated with design and 
quality of the intervention, including how intervention is perceived
The importance of demonstrating PRO efficacy and impact
Both patients and HCP participants felt that PROs could 
support the delivery of person- centred care through 
shared decision- making and management in dialysis 
settings. However, HCP interviewees highlighted the key 
challenge was not the physical collection of PROs, but 
how the data were then used to improve outcomes. For 
patients, it was key that any time spent completing ques-
tionnaires should be rewarded with review and appro-
priate action, that is, not a ‘tick- box’ exercise.
HCPs, particularly nephrologists, extolled the impor-
tance of PROs in research settings.
Intervention flexibility
The topic guide initiated discussions with participants 
on key practical considerations, including frequency 
(of PRO completion), optimal timing (around dialysis), 
preferred setting (home or in centre), favoured mode of 
administration (electronic or paper versions) and inter-
pretation and feedback of the responses.
It was clear from the patients that a fixed means of 
implementing PROs would not meet the requirements 
of this heterogeneous group. Any system would need to 
be flexible while maintaining maximum simplicity. Most 
patients felt they could complete electronic measures if 
required, but some strongly favoured paper options. Most 
interviewees stated that self- completion was possible but 
felt some would need physical or emotional support from 
carers. A few patients indicated a desire for assistance with 
information technology (IT) aspects until they became 
familiar. Several patients alluded to the need to ‘compart-
mentalise’ their dialysis by conducting all dialysis- related 
activity in centre or by having discrete facilities and times 
for dialysis if being treated at home; suggesting that PRO 
completion would need to be undertaken at defined 
times/settings within their schedule. Others were less 
concerned about daily reminders of their disease and 
management, so were open to completion timings/
settings that were more variable.
HCPs discussed the promise of electronic capture to 
support enhanced management of chronic symptoms, 
but some expressed concerns about potentially missing 
acute signs and effectiveness of associated safety reporting 
and actions. Two HHD patients foresaw the potential 
benefits of automated safety alerts associated with elec-
tronic capture. However, one patient noted that it was 
important that any automated information or self- help 
advice should not conflict with information given face to 
face by the doctor.
Participants were asked for their perspectives on 
computer adaptive technology, a type of assessment in 
which questions are generated specifically for each indi-
vidual, using item response theory. This was a new concept 
to nearly all participants, but most quickly grasped the 
underlying theory after a short explanation and were 
supportive of the idea, recognising the potential to stop 
redundant questions and save time. (See table 4 for over-
view of practical considerations.)
Outer setting: the wider societal, economic and organisational 
contexts in which the stakeholders and organisation implementing 
the intervention reside
Identifying outcomes that matter
There was a general agreement among all participants 
that it was important to ensure measurement of ‘what 
outcomes matter most’ to patients.51 There was a broad 
agreement from patients that the example PROs they had 
been provided with were comprehensive in covering the 
key symptoms facing patients undertaking HD. Further-
more, they agreed with findings from the Standardised 
Outcomes in Nephrology (Haemodialysis) initiative 
(SONG- HD) 42 that fluctuations in HRQoL mattered 
more, to them, than biomedical outcomes. The impor-
tance of these outcomes was acknowledged by the HCPs, 
but it was felt that deep exploration of some PRO data 
fell outside the remit of the nephrologist or dialysis nurse 
and there was anxiety about acting outside their compe-
tency and the associated risks of litigation.
The ‘Bigger Picture’
Several patients highlighted problems with continuity of 
care and lack of cohesion between primary care and their 
dialysis provision. One HHD patient felt the use of PROs 
could assist uptake of home therapies by demonstrating 
better overall outcomes/HRQoL for patients managing 
their own dialysis. Participants in both groups reflected 
that PROs could help support shared decision- making 
by targeting and prioritising discussions according to the 
patient’s agenda.
Inner setting: the structural and cultural contexts around where the 
implementation will take place
Compatibility of PRO use and approaches to care in HD settings
Discussing potential implementation and how partici-
pants perceive the current situation as needing change, 
patients and staff alike discussed the approaches to care 
within dialysis settings. Patients clearly described a ‘task 
orientated’ style of care in centre, with a focus on prac-
tically administering HD, versus a more patient- centred 
model discussed by those dialysing at home. HHD patients 
dialysing themselves felt they had developed a level of 
expertise and the increased ‘control’ had improved their 
HRQoL. They indicated current communication path-
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and holistic in their approach to care. Analysis of patient 
and HCP data suggested that time constraints were the 
major reason for a task- based approach in centre with 
both patients and staff exhibiting a desire to complete 
dialysis sessions with as little impediment as possible. 
Correspondingly, most in- centre patients did not feel staff 
had time to have long discussions and some suggested 
PROs might help rectify this. There was no discernible 
variation in the views of the HHD cohort on the practical-
ities of PRO collection.
Part of a wider framework: the ‘information loop’, the role of PROs 
in addressing training needs and health literacy
HCP data analysis highlighted the importance of educa-
tion, training and support for successful implementation. 
It was indicated that while medical staff needed training 
in PRO interpretation, such as rating scales, nurses might 
need a broader programme on use of PROs as well as asso-
ciated chronic disease management. There was disparity 
indicated in the health literacy of the patient group; some 
HHD patients appeared expert in their illness and treat-
ment, while some in- centre patients appeared less confi-
dent in their knowledge.
Characteristics of individuals: factors associated with individuals 
involved in implementation
Previous experience of using PROs
Patients expressed an overall lack of awareness and expe-
rience of PROs. Many had completed annual PREMs but 
highlighted a lack of feedback or action. Some patients 
expressed general anxiety about questionnaire comple-
tion, linked to their experience of externally adminis-
tered questionnaires for other agencies: for example, 
Personal Independence Payment surveys assessing 
entitlement to extra costs associated with long- term ill 
health or disability. When reviewing the example PROs, 
it was noted that some patients, particularly those from 
minority ethnic backgrounds, flagged the potential diffi-
culty around asking about sensitive issues such as sexual 
function. While the participants themselves were happy 
to discuss such issues, they recognised that not all patients 
might be.
All nephrologists interviewed had experience of using 
PROs in research settings, but none had regularly and 
systematically collected PROs in routine care. PRO use 
in any setting was largely a new concept for nursing staff.
There was a confusion around the concepts of PROs 
versus PREMs, expressed by both patients and HCPs. 
Participants found it hard to distinguish experience of 
care from outcomes and used terms interchangeably.
Multidimensional aspects of ESKD and consequent challenges
Many of the patients in the study had multiple comor-
bidities and associated symptoms, reflective of the wider 
HD population. Patients indicated that it was often hard 
to know which symptoms related to their ESKD and/or 
treatment, and which were associated with other diseases 
or advancing age; leading to anxiety about what to raise 
during a consultation. It was suggested that PRO data 
review and feedback gave a chance to discuss symptoms 
and potential causes, thereby potentially providing reas-
surance. However, some clinicians thought it was outside 
their role to manage non- nephrology- related outcomes 
presented by PROs and that it would be difficult to disen-
tangle several, possibly unrelated, symptoms. They feared 
focusing on symptoms that were not currently being expe-
rienced or intractable could cause frustration or anxiety 
for themselves and the patients. Some patients gave a 
contrasting opinion, revealing the chance to be heard, 
even without a solution, was often sufficient to maintain 
the patient–clinician relationship. There was also concern 
that an over- reliance on PROs could result in a distraction 
from other important clinical issues.
The experience of life on dialysis was highly varied, with 
some participants exhibiting signs of depression, anger or 
acceptance, as well as reporting multiple symptoms.
The process of implementation
Supporting the process of implementation
The analysis identified leadership, the identification of 
champions and a ‘bottom up’ approach to communi-
cation and shared solutions among both patients and 
clinicians as key factors supporting implementation. 
All participants emphasised the importance of support 
during completion; however, patients highlighted this 
need not always be delivered by healthcare staff. Peer- to- 
peer support and non- clinical champions, that is, admin-
istrative staff, might assist. HCPs felt a comprehensive 
launch was important and that individual roles should be 
clear. They reflected that senior members of the clinical 
team would be opinion leaders, and any change agents 
would need to understand the dialysis setting. Evaluation 
and reflection were important process components to 
recognise and deal with any unintended consequences.
Overarching themes: barriers and facilitators to effective 
implementation
Across all CFIR constructs, analysis identified potential 
barriers and facilitators to the introduction of PROs.
Potential barriers
Nephrologists cited a lack of evidence base supporting the 
use of PROs in routine kidney care and were concerned 
regarding the risk of overmedicalising the patient experi-
ence. There were perceived time barriers for staff, that is, 
workflow interruptions, additional obligations caused by 
PROs; with nurses perceiving quality time with patients in 
centre as limited. HCP participants argued that nursing 
documentation had lessened available time, as it often 
required recording on digital devices away from the 
bedside. They feared patients were being overburdened 
by questionnaires, particularly the less health literate.
In contrast, patients were often already aware of the 
complications associated with ESKD and HD. Many had 
achieved a degree of acceptance and some were reassured 
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to deal with. Frustration would only arise if, having taken 
time to complete the questionnaires, no action was taken. 
Both groups agreed that IT issues, that is, inability to log 
in, no Wi- Fi, could be a barrier.
Potential facilitators
Several HCPs considered how PROs might work to deliver 
a relative advantage over current systems to support more 
patient- centred care. Participants felt PROs could be 
a communication tool—acting like a ‘tin opener’; but 
requiring that responses be carefully probed, highlighting 
that this required appropriate skills and training. Others 
saw the measures as an aide- mémoire which could help 
target the consultation and even save time; as could the 
possibility of remote management of care using ePROs. 
Perhaps, most importantly, PROs were seen by both 
patients and HCPs as a way to get to know the patients 
and hence deliver more meaningful care.
DISCUSSION
There is a growing body of published, peer- reviewed liter-
ature exploring the experiences of both kidney patients 
and multidisciplinary kidney HCPs with ePROs.13 17 23 26 27 52 
Previous studies have included non- dialysis- dependent 
CKD and peritoneal dialysis populations,17 23 27 evalu-
ating existing ePROs and associated delivery systems. 
This paper adds to the corpus by using semistructured 
interviews to gain rich data to inform and optimise future 
ePRO implementation in an HD population naïve to 
ePRO collection and clinicians unused to routine and 
systematic ePRO use.
The key findings of this study are that while patients 
and HCPs support the concept of PROs, further evidence 
of their potential benefit is required for effective imple-
mentation. It emphasises that any system should be flex-
ible and measure what matters most to patients. Most 
importantly, the data collected should be acted on. There 
was a general lack of awareness and experience of PROs 
particularly among patients and nurses, with concern 
among the HCPs that PRO capture may highlight issues 
they might have neither the experience nor resources to 
manage. Therefore, a comprehensive implementation 
strategy is required to support any delivery, which involves 
strong leadership, patient and clinician involvement and 
ongoing training.
This study highlighted the importance of getting ‘buy 
in’, that is, gaining acceptability, from these stakeholders. 
This could be achieved by demonstrating evidence 
on their potential benefits thereby increasing trust to 
warrant practice change. Clinicians particularly ques-
tioned whether positive effects on survival, reported QoL, 
patient–clinician communications and cost efficiencies 
demonstrated in oncology29 53–55 could be replicated in 
HD settings.
The body of evidence around ePROs in nephrology is 
emerging. Studies from North America demonstrate the 
feasibility of electronic capture of PROs in HD19 24 and an 
Australian pilot study is currently exploring the feasibility 
and acceptability of ePRO capture and feedback among 
patients receiving HD in the Symptom Monitoring With 
Feedback Trial.20 In advanced CKD populations, the 
Renal Electronic Patient Reported Outcome Measures 
(RePROM) study is piloting the use of an ePRO for 
remote symptom monitoring in the UK,56 while the Ambu-
Flex telePRO system is used to manage renal follow- up 
in Denmark.25 Aiyegbusi et al17 explored key stakeholder 
perspectives on the use of PROs in these predialysis 
patients and their findings are consistent with this study, 
particularly regarding potential benefits and administra-
tive aspects; suggesting PRO data collection early in the 
patient pathway can be instituted and continue as illness 
advances through to renal replacement therapy or even 
conservative care.
A review and synthesis of evidence is currently being 
undertaken to investigate how PROs might work to 
enhance patient- centred care in renal settings, to offer 
strategy and guidance at individual and aggregate levels 
of decision- making.57 For effective multiple uses of data, 
implementation needs to be viewed within the context of 
complex data linkage and accessibility issues. Studies in 
the UK and Australia are currently exploring and testing 
such linkage of symptoms and QoL data to the Australia 
and New Zealand Dialysis and Transplant Registry and 
UK Renal Registry.20 22 58
However, the purpose of data collection must be clear. 
Participants in this study confused the concepts of PROs 
versus PREMs, understandable given that experience of 
undertaking HD is intricately linked to both HRQoL and 
symptoms. The integrated use of both measures, side 
by side, warrants further investigation. Anxieties about 
purpose and data sharing could affect patient engage-
ment; clear communication of roles and expectations 
should be undertaken.
While guidance exists on what outcomes to measure 
in research5 6 and routine practice9 this has not neces-
sarily been centred on routine capture and feedback to 
guide individual care. Consequently, it is not clear which 
measure(s) should be used to capture data in a non- 
burdensome way, while providing sufficient measurement 
properties to support both single patient monitoring and 
aggregation of data where required, meaning further 
enquiry is needed.
The general lack of awareness and experience of PROs 
and concern that PRO capture may highlight issues that 
HCPs should not or cannot deal with, leads to a signif-
icant finding that PRO implementation must sit within 
a broader educational framework. PROs could be used 
to support wider initiatives and training, especially in the 
nursing group, who can then cascade information and 
self- management skills to patients, thereby increasing 
overall patient health literacy. This could be considered as 
closing an ‘information loop’. There is already evidence 
that patient education is associated with better patient 
outcomes59 and new strategies and quality improvement 
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aiming to support patients receiving in- centre HD to 
be more independent and confident in participating in 
aspects of their own care.60 Potential barriers are cost and 
resources, but increasingly, accredited online learning 
facilities are available. However, it is acknowledged, staff in 
this study indicated a preference for face- to- face training. 
Education and training on PROs would be needed for all 
stakeholders.
This study identified time and workflow interruptions 
as key barriers to implementation. Rotenstein et al61 
found that following initiation of routine PRO collection 
in surgical settings, such concerns shifted as clinicians 
became comfortable with new processes. There was even 
a suggestion that PROs could enhance physician satisfac-
tion and prevent ‘burnout’.61 Tong et al52 interviewed the 
nephrologists, who also identified resource constraints 
and uncertainties in how to prioritise, measure and 
manage a range of competing comorbidities and broader 
QoL outcomes in a clinical setting that is technically 
demanding and traditionally focused on biochemical 
factors; findings mirrored by this study. Such anxieties 
will need addressing.
During the SARS- CoV-2 pandemic, data from the UK 
Renal Registry showed that patients undergoing HD 
experience a relative risk of mortality of 45.5% compared 
with the general population.62 This vulnerable population 
has been unable to effectively shield, requiring regular 
dialysis treatment with associated risks around shared 
transport and waiting areas. Various strategies have been 
employed to reduce risks63 but new ways of care delivery 
were required. The pandemic has irrevocably changed 
healthcare, with increased use of virtual services64 and 
remote clinic visits. The addition of ePROs to readily avail-
able biomedical data means that clinicians could more 
effectively deliver patient- centred care without the neces-
sity of the patient being physically present. This study also 
suggests that remote symptom monitoring could offer 
patients the safety and confidence to dialyse at home and 
arguably ePROs could assist the HHD service in main-
taining its patient- centred approach while serving ever 
increasing numbers.
There are limitations to this study. Participants needed 
to be English speakers; this could affect transferability of 
findings. Views of carers were not specifically sought but 
their influence and importance were clearly identified by 
patients, suggesting further research targeting this group 
is warranted. Critically, data collection took place before 
SARS- COV-2 pandemic and experiences and percep-
tions around digital data capture and new approaches to 
healthcare delivery may well have shifted.
To conclude, the SARs- COV-19 pandemic has caused 
an irreversible shift in healthcare delivery, with increased 
use of digital communication and assessment. While the 
nephrology community, both patients and HCPs, are 
largely supportive of the concept of ePROs, there remain 
caveats to their routine and systematic use. Stakeholders 
need to be convinced by empirical evidence, consid-
ering the best available measures and methodological 
considerations. By exploring the experiences, views and 
perceptions of major stakeholders, this study identified 
key factors at organisational and individual levels which 
would assist effective implementation of ePROs. Further 
research will then be required to evaluate any subsequent 
ePRO interventions to empirically demonstrate the 
impact and benefit of their use to the dialysis community.
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PROM-HD Study 
Using patient reported outcome measures (PROMs) to promote quality of care 
and safety in the management of patients with established kidney disease 
requiring treatment with haemodialysis 
Topic Guide – Patient Participant Interviews 
Research Objectives 
To explore the feasibility of using routine PROM assessment to aid the management of 
patients with established renal failure undergoing HD 
Respondent Profile 
18 years or over, patients who are receiving renal replacement therapy in the form of 
HD, who meet the study inclusion/exclusion criteria 
Logistics 
Face-to face interviews:  place, date, and time (start and end) of the interviews to be 
recorded.   
Telephone interviews: write the name, title, telephone number of the respondent and 
record data and time (start and end time) of interview. 
Introduction 
Introduce self as a Nurse Researcher but explain that whilst I have a nursing background 
I am not part of their direct healthcare team, so please feel to talk openly and honestly. 
Participants should be reassured about the confidential nature of the interview and that 
all comments will be anonymised before use. 
Topics and areas of questioning 
A: Awareness of PROMs 
1. Have you ever completed questionnaires about your QoL or experiences of 
receiving dialysis before?  
 
2. Having looked at the sample questionnaires – do they capture the things you 
think are most important about living with kidney disease and being on dialysis 
 
3. Do you think the collection of PROM questionnaires would be beneficial? Do you 
think the capture of these outcomes is important?  
 
 
B. Practical Aspects around PROM collection 
 
1. Would you be able to complete a PROM questionnaire successfully on your own, 
and if not, how much assistance do you think you would require?  
 
2. How often should they be completed and how long should completion take? 
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3. Where and when would you want to complete the PROMs i.e. at home? At the 
Unit? Before or during dialysis? 
    
4. How should PROM data be collected i.e. in paper or electronic formats such as 
mobile app or telephone recognition systems? 
 
 
C. Feedback of PROM data 
1. How would you like to receive feedback from the clinical team on your PROM 
data? i.e. email, letter, graphs in person etc. 
 
 
D. Barriers or facilitators  
 
1. What do you think are the likely factors (barriers and facilitators) that may 
improve or discourage the completion of PROMs? 
 
2. What do you think are the issues about PROM collection in different patient 
groups (e.g. older patients, patients of non-white ethnicity)? 
 
E. Use of PROMs in Research 
1. Have you have been involved in PROM collection for research purposes?  
 
2. Should PROMs that collect data for routine clinical and research purposes be 
different?  
 
3. Do you think any of the practical considerations change when you are collecting 
PROMs for research rather than as part of routine practice? i.e. would you be 
prepared to complete them more often for research  
 
4. Are there any special considerations to be given to feedback when using PROMs 
in a research setting? 
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PROM-HD Study 
Using patient reported outcome measures (PROMs) to promote quality of care 
and safety in the management of patients with established kidney disease 
requiring treatment with haemodialysis 
Topic Guide – HCP Interviews 
Research Objectives 
To explore the feasibility of using routine PROM assessment to aid the management of 
patients with established renal failure undergoing HD 
Respondent Profile 
Healthcare Professionals (HCPs) who meet the study inclusion/exclusion criteria.  
Logistics 
Interview: place, date, and time (start and end) of the interviews to be recorded.  
Introduction 
Introduce self as a Nurse Researcher but explain that whilst I have a nursing background 
I am not part of the direct healthcare team, so please feel to talk openly and honestly. 
Participants should be reassured about the confidential nature of the interview and that 
all comments will be anonymised before use. 
Topics and areas of questioning 
A: Awareness of PROMs 
1. Have you ever been involved in the collection of PROMs or data regarding QoL and 
patient experience before?  
 
Do you think the collection of PROM questionnaires would be beneficial? 
 
Do you think the capture of these outcomes is important? What do you think about 
the current measures available and the use of core outcome sets. 
 
Do you think they could help focus a consultation? Should a ‘good’ clinician already 
be able to elicit those outcomes that are important to a patient? Would PROMs alter 
the way a clinician talks or engages with a patient? 
 
If yes, how, do you think they could help improve care for a group of patients? 
 
Do you think they could assist in the multidisciplinary team (MDT) care/follow up of 
the patient? 
 
How much time do you spend talking to patients in a typical consultation? Would you 
like to spend more/less? 
 
2. Having looked at the sample questionnaires – do they capture the things you think 
are most important about living with kidney disease and being on dialysis from your 
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perspective as a MDT member? 
 
a. Are there specific aspects of dialysis care that you think would be effected by 
the use of PROMs 
 
b. How do you think PROMs differ from PREMs? Do you think collection of one is 
more important than the other? 
 
B. Practical Aspects around PROM collection 
 
1. Do you think most patients would be able to complete a PROM questionnaire 
successfully on their own, and if not, how much assistance do you think they 
would require and from whom? Could assistance affect the responses? 
 
2. How often should they be completed and how long should review of the results 
take? 
 
3. Where and when would you want the PROMs completed i.e. at home?  Before or 
during dialysis? 
    
4. How should PROM data be collected i.e. in paper or electronic formats such as 
mobile app or telephone recognition systems? 
 
C. Feedback of PROM data 
1. Who would be the best member of the MDT to review the data initially? What 
about alerts? How should they be managed? Some staff said they don’t have time, 
is that true? 
 
2. What might be the best way the feedback the PROM data to the (a) clinical team, 
(b) patient? i.e. email, letter, graphs in person etc. 
 
3. How to do you deliver your QA results? 
 
4. How do you feel dealing with problems that you can’t solve – do you feel there are 
areas outside your area of expertise you would not want to discuss? Is listening 
enough? 
 
5. Specifically, what PROM data do you think would be important within (a) a clinic 
environment, (b) an MDT meeting, and how might it be presented? E.g. line 
graphs, bar charts, raw tabulated data etc. 
 
6. Could they be used to show longitudinal trends? Do you think they would be able 
to pick up ceiling effects or sensitive changes? 
 
D. Barriers or facilitators  
1. What do you think are the likely factors (barriers and facilitators) that may 
improve or discourage the completion of PROMs? IT issues/time? Importance of 
leadership during any implementation phase 
 
2. Is there a risk we are going to overburden patients with multiple questionnaires? 
Have you heard of CAT/item banking? 
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3. What is the best way to implement into your workflow – could they affect your 
work flow patterns? 
 
4. Would you want educating about PROMs – what form would that learning take? 
What specifically would you want more information on? Theory behind collection 
of PROS, Core outcome sets? Measures available, how they may be used in 
routine care?  
Are there opportunities to undertake advanced communications training? 
 
5. What do you think about are the key issues about PROM collection in different 
patient groups (e.g. older patients, patients of non-white ethnicity)? 
 
E. Use of PROMs with patients undergoing Home HD 
 
1. In your opinion, how do patients dialysing at home differ from those dialysing in 
satellite units? Are they better at ‘coping’, dealing with change or is it their 
support structures? Do you think there is utility measuring PROs with this group 
of patients in particular? Role of carers in this group, how much should they be 
involved in the process? 
 
2. Would any of your answers differ for patients undergoing Home HD in terms of 
when, where, how often, who should review and provide feedback? 
 
3. Do you think Home HD patients are more likely to engage with digital technology? 
 
 
F. Use of PROMs in Research 
1. Have you have been involved in PROM use for research purposes? do you know 
how the measurement tool was chosen? Do you think it captured outcomes that 
were relevant for the research project? 
 
2. Do you think it would be a good idea to use core outcome sets for renal trials? 
Should outcomes and the associated PROM that collects them differ between use 
for routine clinical and research purposes?  
 
3. Do you think any of the practical considerations change when you are collecting 
PROMs for research rather than as part of routine practice? i.e. how often and 
where they are completed 
 
4. Are there any special considerations to be given to feedback when using PROMs 
in a research setting? 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
1 Innovation Characteristics                       
1A Innovation Source            x      x     
1B Evidence strength and quality / / / / / / / / / / / / / / / / / / / / / / 
1C Relative 
Advantage 
Perception of advantage 
 
Intractable problems 


































































Adaptability of intervention 
Use within research 
Importance of choices in how 































































1E Trialability / / / / / / / / / / / / / / / / / / / / / / 
IF Complexity        x           x     
































































































Number invited/Number participating  
Reasons for non-participation 
 
Duration of patient interviews (min) 
 
Patient Saturation Data 
No of codes generated 




Did not meet eligibility criteria, did not want to participate (transport issues, did not want to do research) 
Range 24-84 




Note n=17  
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 
Setting 
Timing 





Review and Feedback 




































































































































































































IH Cost                  x     
2 Outer Setting                       

































































































2B Cosmopolitanism   x    x   x    x     x    
2C Peer Pressure / / / / / / / / / / / / / / / / / / / / / / 
2D External policies and incentives / / / / / / / / / / / / / / / / / / / / / / 
3 Inner Setting                       
3A Structural Characteristics               x        
3B Networks and 
Communications 
Nature and Quality  
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 













































































































4 Characteristics of Individuals                       
Knowledge and beliefs x x x x   x x x  x  x x x x x x x x x  
Self-efficacy Ability to self-complete 
Patient as an Expert 






































stage of change 
Previous experience of PROMs 
usage 
x   x x x  x x x x x x x x x x x x x x x 
Individual identification with organisation x x  x x x x x x x x x x x  x   x x x x 
Other personal 
attributes 
Multidimensionality of ESKD: 
Symptomology 



































































5 Process                       





Formally appointed leaders 
Champions 
External Change Agents 
Key Stakeholders 
Innovation Participants 



























































































































































5C Executing / / / / / / / / / / / / / / / / / / / / / / 
5D Reflecting and Evaluating / / / / / / / / / / / / / / / / / / / / / / 
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First time data coded to node in NVIVO x 
Nothing coded to node in NVIVO / 
Nothing coded to node in NVIVO / 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
1 Innovation Characteristics                  
1A Innovation Source     x          x   
1B Evidence strength and quality x    x    x  x  x x x x x 
1C Relative Advantage  
 
































1D Adaptability  
 
Use within research 






















1E Trialability                x  
IF Complexity x    x x  x  x      x  




























































































Number invited/Number participating  
Reasons for non-participation 
 
Duration of patient interviews (min) 
 
Patient Saturation Data 
No of codes generated 




Competing clinical commitments 
 
Range 29-63 







Note n=17  
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Outcomes that matter 
Safety Alerts 
Sensitivity 
Computer Adaptive Technology 






































































































































IH Cost             x  x   
2 Outer Setting                  




























































2B Cosmopolitanism   x x  x x     x      
2C Peer Pressure                  
2D External policies and incentives   x  x x x x     x x  x x 
3 Inner Setting                  
3A Structural Characteristics x x x x  x x    x x x x    
3B Networks and Communications x  x x x  x x x x x x  x x  x 
3C Culture x x x  x x x   x x x   x x x 
3D Implementation Climate  
Tension for change 




























































































3E Readiness for Implementation Leadership Engagement  x         x       
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 
Available Resources 























4 Characteristics of Individuals                  
Knowledge and beliefs x x x  x  x x x   x  x  x x 
Self-efficacy  



































Individual stage of change Previous experience of PROMs usage x x x x x x x x x x  x x x x x  
Individual identification with organisation  x x      x x  x      
Other personal attributes x x x x  x x    x x x x x x  
5 Process                  





Formally appointed leaders 
Champions 



























































5C Executing                  
5D Reflecting and Evaluating               x   
                  
 
First time data coded to this node in NVIVO x 
Nothing coded to this node in NVIVO  
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